

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name----EyeYon Medical--- * Website----www.eye-yon.com----- *

CEO name---Nahum Ferera----- * Cell phone number----+972-543023333--- *

Select a CATEGORY: Medical Devices *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

1. Longevity - How to Complete the Centenarian Decathlon?
12. Bio Convergence - Everything That Rises Must Converge.

You may delete the section instructions, leaving **only the bolded bullet title**
Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**
EyeYon Medical provides innovative, patent protected solutions that proved feasibility for corneal healing, including corneal edema. More than 13 million people are on a waiting list for cornea from a human donor, due to a significant global shortage of corneas.
- **Core Technology**
EndoArt® is an the only synthetic endothelial layer that replaces the need of human tissue for curing corneal edema using a polymer implant attached to the corneal surface. The minimal invasive implantation of the EndoArt® prevents transfer of fluids into the cornea, thus avoiding the creation of edema in the ailing eye.
- **Product Profile/Pipeline**
EndoArt® - is now CE approved and found to be both safe and effective in humans for long term follow up +2 years. Phase 2 trials are being conducted in several sites globally. Potential market estimation of > \$8B.
- **Business Strategy**
To date, there are not enough solutions to help the suffering corneal edema patients. EyeYon's solutions address an unmet clinical need. One of these solutions, the EndoArt® is a revolutionary product, eliminating the need for human source cornea transplant.
- **What's Next?**
EyeYon Medical completed \$30M C round led by strategics. The funds will support extensive clinical trials to support FDA & NMPA approval. EyeYon Medical expends its activity toward US and China.

